AstraZeneca ’s faslodex receives EU approval for advanced breast cancer treatment

The European Commission (EC) has approved AstraZeneca ’s faslodex (fulvestrant) for the treatment of oestrogen-receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news